2017
Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis
McCommis KS, Hodges WT, Brunt EM, Nalbantoglu I, McDonald WG, Holley C, Fujiwara H, Schaffer JE, Colca JR, Finck BN. Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis. Hepatology 2017, 65: 1543-1556. PMID: 28027586, PMCID: PMC5397348, DOI: 10.1002/hep.29025.Peer-Reviewed Original ResearchConceptsStellate cell activationPeroxisome proliferator-activated receptor γProliferator-activated receptor γNonalcoholic steatohepatitisMitochondrial pyruvate carrier 2Cell activationRodent modelsReceptor γDevelopment of NASHNonalcoholic fatty liver diseaseDose-limiting side effectHepatic stellate cell activationFatty liver diseaseInsulin-sensitizing thiazolidinedionesLiver of miceLiver-specific deletionExpression of markersTrans fatty acidsMetabolic syndromeLiver diseaseHepatocyte dysfunctionHepatic fibrosisLiver fibrosisPharmacologic developmentMouse model
2013
A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responses
Wei J, Zhu H, Komura K, Lord G, Tomcik M, Wang W, Doniparthi S, Tamaki Z, Hinchcliff M, Distler JH, Varga J. A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responses. Annals Of The Rheumatic Diseases 2013, 73: 446-454. PMID: 23515440, PMCID: PMC4028127, DOI: 10.1136/annrheumdis-2012-202716.Peer-Reviewed Original ResearchMeSH KeywordsAdipogenesisAdultAnimalsBiopsyCells, CulturedCollagenDisease Models, AnimalDrug Evaluation, PreclinicalFemaleFibroblastsFibrosisHumansInfant, NewbornMiceMice, Inbred C57BLOleanolic AcidOrgan Culture TechniquesPPAR gammaProto-Oncogene Proteins c-aktScleroderma, SystemicSignal TransductionSkinTransforming Growth Factor betaConceptsSkin organ cultureHuman skin organ cultureAntifibrotic effectsDermal fibrosisExperimental fibrosisOrgan culturePeroxisome proliferator-activated receptor γModulation of fibrogenesisProliferator-activated receptor γHuman skin equivalentsPotential new therapiesPotential therapeutic strategyFibrotic gene expressionSynthetic oleanane triterpenoidComplementary mouse modelsControl of fibrosisPersistent fibroblast activationGrowth factor βTGF-β signalingEffects of CDDOSystemic sclerosisBleomycin injectionFibrogenic responseFibrotic activityMurine model
2012
Response of Adipose Tissue to Early Infection With Trypanosoma cruzi (Brazil Strain)
Nagajyothi F, Desruisseaux MS, Machado FS, Upadhya R, Zhao D, Schwartz GJ, Teixeira MM, Albanese C, Lisanti MP, Chua SC, Weiss LM, Scherer PE, Tanowitz HB. Response of Adipose Tissue to Early Infection With Trypanosoma cruzi (Brazil Strain). The Journal Of Infectious Diseases 2012, 205: 830-840. PMID: 22293433, PMCID: PMC3274374, DOI: 10.1093/infdis/jir840.Peer-Reviewed Original ResearchMeSH KeywordsAdipocytesAdiponectinAdipose Tissue, BrownAdipose Tissue, WhiteAnimalsChagas DiseaseChemokinesCytokinesI-kappa B KinaseMaleMiceMitogen-Activated Protein KinasesNF-kappa BPPAR gammaReceptors, ChemokineRNA, MessengerSignal TransductionToll-Like Receptor 4Toll-Like Receptor 9Trypanosoma cruziConceptsWhite adipose tissueBrown adipose tissueAdipose tissueCruzi infectionNuclear factor kappa B (NF-κB) levelsToll-like receptor 4Peroxisome proliferator-activated receptor γProliferator-activated receptor γMRNA levelsTrypanosoma cruzi infectionMessenger RNA levelsReceptor 4Adipocyte sizeFat massHigher parasite loadsReceptor γEarly infectionExpression of componentsInfectionB levelsLipid accumulationRNA levelsParasite loadEarly targetProtein kinase pathway
2003
Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study
Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP. Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study. Breast Cancer Research And Treatment 2003, 79: 391-397. PMID: 12846423, DOI: 10.1023/a:1024038127156.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerSerum tumor markersBreast cancerTumor markersTumor differentiationDisease progressionAdvanced breast cancer refractoryElevated serum tumor markersRefractory metastatic breast cancerPeroxisome proliferator-activated receptor γBreast cancer refractoryRefractory breast cancerPhase II studyPercentage of patientsProliferator-activated receptor γDifferent patient populationsCancer refractoryChemotherapy regimenII studyObjective responseSystemic therapyPO QDHormonal regimensHepatic toxicityPatient population
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply